Q2
AXGN — Q2 2026 Financial Report Analysis
Axogen grew Q2 2026 revenue 23.1% to $69.7M and raised full-year guidance to at least $279M, but a costlier biologic Avance and faster expense growth cut gross margin to 72.7% and produced a $1.5M net loss.